title: Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
authors.forename: Pierre
authors.initials: P
authors.lastname: Laneuville
authors.forename: Clifford
authors.initials: C
authors.lastname: Dilea
authors.forename: Ophelia Q P
authors.initials: OQ
authors.lastname: Yin
authors.forename: Richard C
authors.initials: RC
authors.lastname: Woodman
authors.forename: Jürgen
authors.initials: J
authors.lastname: Mestan
authors.forename: Paul W
authors.initials: PW
authors.lastname: Manley
mesh_terms: D001549:Benzamides; D002470:Cell Survival; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D066298:In Vitro Techniques; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl